Drugs / IDH305
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02826642 | Aug → Nov 2016 | acute myeloid leukemia | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT02381886 | Mar 2015 → Dec 2016 overdue | — | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02977689 | Apr 2018 → Apr 2020 | glioma | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT02987010 | Jan 2017 → Jan 2019 | glioma | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDH305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826642 ↗ |
| Action | Inhibit | “mutant-selective allosteric IDH1 inhibitor” PMID 35353219 ↗ Mar 2022 |
| Modality | Small molecule | — CHEMBL4167360 ↗ |
| Route | Oral | “IDH305 is an orally bioavailable” PMID 35353219 ↗ Mar 2022 |
| Target | IDH1 | “mutant-selective allosteric IDH1 inhibitor” PMID 35353219 ↗ Mar 2022 |